TIGIT, CD155, & CD226
Promising Targets for Cancer Immunotherapies
It’s possible someone you know has benefited from cancer treatments based on checkpoint receptors. Therapeutic antibodies targeting PD-1 and CTLA-4 pathways have already added years to the lives of lucky patients. Unfortunately, not everyone responds to these treatments. This resistance drives the search for new therapies to extend the successes of existing PD-1 and CTLA-4-based treatme...
Methods For Drug Discovery
Immunotherapies based on targeting the PD-1:PD-L1 immune checkpoint pathway are having clinical impact and are giving new hope to cancer patients. However, positive response to treatment is not guaranteed and resistance remains a concern. Improving outcomes based on immunotherapy requires multiple approaches for manipulating the complexities of the immune system and tumor microenvironment. To meet these challenges, a series of r...
Conferences & Events
Combination therapy for cancer: using immunotherapy and viruses webinar
April 18, 2024 (1:00 PM-2:00 PM Eastern Time)
While immunotherapy activates the immune system against cancer cells, its efficacy varies among patients. Oncolytic viruses selectively infect cancer cells and induce immunogenic cell death, making them an appealing adjunctive approach to enhance therapeutic responses. However, translating research findings into clinical success has...
Immune Checkpoint Molecules
Immune checkpoint molecules are crucial components of the immune system that regulate the intensity and duration of immune responses but have been usurped by cancer cells and pathogens to evade the immune system.
Immune checkpoint molecules are crucial components of the immune system that regulate the intensity and duration of immune responses but have been usurped by cancer cells and pathogens...
The Promise of NK Cell Therapeutics
Introduction
NK cells are the first line of defense against cancer and have been in the spotlight as a cancer therapy in the last decade. Their advantages versus T cells, such as their safety profile and not requiring MHC (Major Histocompatibility Complex)-antigen stimulation to become cytotoxic, have made NK cells attractive. However, as with T cells, the TME (tumor microenvironment) can suppress their activity, and infiltration into solid tumors is s...
LAG3 as a Cotherapy for Immune Checkpoints
Cotherapy with PD-1
Therapeutic antibodies targeting the immune checkpoint receptors PD-1 and CTLA4 substantially changed the prognosis for many cancer patients. When successful, these treatments extend lives. Still, cancer is relentless. Only a relatively small number of patients respond or have substantial remission when these treatments are used as monotherapies.
Much of the current research on immunomodulating r...
Combining Therapies for Targeting Immune Checkpoints
| IMMUNE CHECKPOINTS | | KINASES | | PARPS | | HDACS | | CAR T-CELL THERAPY |
Cancer is a balance between the defens...
Citations
This page contains a list of scientific journal articles that have cited BPS products and services since 2013. We would like to congratulate all our loyal customers on their contributions to the scientific community. Our customers are truly amazing and dedicated scientists and this is evidenced by the outstanding research they are doing.
Search By Product Name or Catalog Number
Name
Title
10X HAT Assay Buffer (50095...
Immunotherapy Biochemical Screening Services
Immunotherapy is a type of medical treatment that engages the body's immune system to fight diseases, such as cancer, infections, and autoimmune disorders. It works by either stimulating the immune system to attack cancer cells or other disease-causing agents, or by using synthetic proteins or antibodies to target specific molecules on the surface of cancer cells or other pathogens. Immunotherapy has shown prom...
